Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.66 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.66 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.56 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.47 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68902 | 0.86 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL20642216 | 0.85 | CYP4F2 (0.68) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL27509756 | 0.84 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL13879886 | 0.84 | CYP4F2 (0.66) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL13159630 | 0.84 | CYP4F2 (0.66) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL2084274 | 0.83 | MAPT (0.58) | CYP4Z1GAAMAPT | |
| SCHEMBL6984766 | 0.83 | CYP4F2 (0.64) | CYP4F2CYP4A11CYP4Z1MITFTDP1 | |
| Hydrochloric Acid SCHEMBL7908695 | 0.82 | MAPT (0.61) | CYP4Z1GAAMAPT | |
| SCHEMBL2082531 | 0.82 | CYP4F2 (0.51) | CYP4F2CYP4A11CYP4Z1TDP1SYK | |
| SCHEMBL23582617 | 0.81 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090137021-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-05-28 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-7144911-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS LLC (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
| US-20040180906-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-16 | — | — | US | disclosed |
| US-20040171075-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | CYP4F2 4506/4885CYP4A11 3582/4885CYP4Z1 4162/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885CYP4Z1 3985/4885 |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | CYP4F2 3868/4885CYP4A11 2994/4885CYP4Z1 4125/4885 |
| US-20040180906-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885CYP4Z1 3985/4885 |
| US-20090137021-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885CYP4Z1 3985/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | CYP4F2 2776/4885CYP4A11 1638/4885CYP4Z1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.